Go Deep
Ajanta Pharma Limited
Ajanta Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 19,222 | 38.8 | 9.73 | 0.06 | 3,525.20 |
| Sep 2026 | 19,222 | 38.8 | 9.73 | 0.06 | 3,525.20 |
| Sep 2026 | 19,222 | 38.8 | 9.73 | 0.06 | 3,525.20 |
| Oct 2026 | 19,444 | 39.4 | 9.88 | 0.06 | 3,581.00 |
| Oct 2026 | 19,215 | 37.6 | 9.41 | 0.06 | 3,410.10 |
Ajanta Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 16,259,600,000.0 | 14,216,400,000.0 | 13,748,400,000.0 | 13,026,500,000.0 |
| Net Profit | 3,342,200,000.0 | 2,667,000,000.0 | 2,737,700,000.0 | 2,553,400,000.0 |
| EPS | 26.8 | 21.4 | 21.9 | 20.4 |
Ajanta Pharma Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 54,072,600,000.0 | 45,875,100,000.0 | 41,615,900,000.0 | 37,075,200,000.0 | — |
| Net Profit | 10,560,000,000.0 | 9,203,900,000.0 | 8,161,700,000.0 | 5,879,800,000.0 | — |
| EPS | 84.5 | 73.6 | 64.8 | 45.9 | — |
Ajanta Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 61,548,400,000.0 | 50,149,500,000.0 | 46,383,900,000.0 | 46,790,200,000.0 | — |
| Total Liabilities | 16,277,500,000.0 | 12,246,600,000.0 | 10,710,200,000.0 | 12,910,300,000.0 | — |
| Total Equity | 45,270,900,000.0 | 37,902,900,000.0 | 35,673,700,000.0 | 33,879,900,000.0 | — |
Owes vs Owns
Ajanta Pharma Limited owed ₹0.26 for every ₹1 it owned in Mar 2026, down from ₹0.28 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.26× | 0.24× | 0.23× | 0.28× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ajanta Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 10.8%Receivables 30.1%Inventory 15.2%Fixed assets (tangible) 34.5%Intangible assets 0.7%Other assets 8.7%
How it's funded — Mar 2026
Short-term debt 3.4%Long-term debt 0.6%Payables 8.8%Other liabilities 13.5%Shareholders' equity 73.6%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 663.1 | 613.8 | 459.5 | 840.1 |
| Receivables | 1,853.9 | 1,182.7 | 1,246.8 | 1,056.9 |
| Inventory | 938.5 | 903.9 | 828.4 | 815.6 |
| Fixed assets (tangible) | 2,120.5 | 1,900.5 | 1,728.9 | 1,698.2 |
| Intangible assets | 41.6 | 46.5 | 14.7 | 7.8 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 537.2 | 367.6 | 360.1 | 260.5 |
| Liabilities & equity | ||||
| Short-term debt | 212.0 | 2.6 | 1.5 | 0.2 |
| Long-term debt | 39.4 | 34.7 | 0.0 | 1.2 |
| Payables | 544.3 | 454.2 | 463.2 | 422.8 |
| Other liabilities | 832.0 | 733.1 | 606.3 | 866.8 |
| Shareholders' equity | 4,527.1 | 3,790.3 | 3,567.4 | 3,388.0 |
| Net tangible assets | 4,485.5 | 3,743.8 | 3,552.7 | 3,380.2 |
Ajanta Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 5,291,900,000.0 | 11,572,300,000.0 | 7,850,700,000.0 | 7,921,100,000.0 | — |
| Investing Activities | -4,289,200,000.0 | -3,765,200,000.0 | 653,900,000.0 | -5,596,000,000.0 | — |
| Financing Activities | -1,679,200,000.0 | -7,334,100,000.0 | -10,510,600,000.0 | -1,082,000,000.0 | — |